Avalo Therapeutics, Inc. — Form D

Avalo Therapeutics, Inc. of ROCKVILLE, MD, a company, filed a Form D exempt-offering notice with the SEC on 2017-05-08. The offering totals $5.0M, of which $5.0M was reported sold. Industry: Biotechnology.

Offering

Issuer

Officers, directors & promoters (52)

Showing 25 of 52 people.

NameRoleLocation
THOMAS E AASENDirectorBALTIMORE, MD
Eugene A BauerDirectorSan Rafael, CA
Isaac A BlechDirectorCITY OF INDUSTRY, CA
PHIL E GUTRYDirectorBALTIMORE, MD
Uli HacksellDirectorWAKE FOREST, NC
MAGNUS E PERSSONDirectorBALTIMORE, MD
Uli HacksellExecutive OfficerWAKE FOREST, NC
JOHN E KAISERExecutive OfficerBALTIMORE, MD
RONALD E MARCUSExecutive OfficerBALTIMORE, MD
MARIAM E MORRISExecutive OfficerBALTIMORE, MD
John KaiserExecutive OfficerResearch Triangle Park, NC
Behshad SheldonDirectorMalvern, PA
CHRISTOPHER SULLIVANExecutive OfficerNew York, NY
Eugene BauerDirectorRedwood City, CA
Magnus PerssonDirectorBeachwood, OH
June Almenoff, M.D., Ph.D.DirectorRockville, MD
Mitchell ChanDirectorRockville, MD
Jonathan Goldman, M.D.DirectorRockville, MD
Aaron KantoffDirectorRockville, MD
Gilla Kaplan, Ph.D.DirectorRockville, MD
Magnus Persson, M.D., Ph.D.DirectorRockville, MD
Samantha TruexDirectorRockville, MD
Garry Neil, M.D.DirectorRockville, MD
Garry Neil, M.D.Executive OfficerRockville, MD
Thomas AasenDirectorResearch Triangle Park, NC

Other filings by this issuer (5)

FiledFormOfferingSold
2024-04-09D$200.0M$130.6M
2016-09-16D$15.0M$1.0M
2014-07-21D$33.3M$16.3M
2013-09-06D$10.0M$6.8M
2012-04-04D$22.5M$22.1M

More